Ecuador has approved the use of Chinese vaccine company CanSino Biologics Inc's (HKG: 6185) COVID-19 vaccine, Reuters news agency reported on Wednesday.
The President of Ecuador, Guillermo Lasso, had announced the purchase of six million doses of the CanSino shot, with the aim of vaccinating nine million people in the first 100 days of his government.
The Ecuador government is also negotiating the purchase of 18 million doses of Russia's Sputnik V COVID-19 vaccine and is asking pharmaceutical companies to speed up the delivery of doses they had previously agreed to provide.
According to Ecuador's health ministry, so far the country has vaccinated over a million people.
Ecuador expects to receive another 814,000 COVID-19 vaccines this week as part of deals already negotiated with laboratories, Reuters added.
Brii Bio acquires BRII-179 IP rights
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
Orexo partners with Abera to develop nasal powder vaccines
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Sanofi's combination vaccine candidates for flu and COVID-19 get Fast Track Designation
hVIVO secures GBP11.5m RSV contract
Novavax sells Czech manufacturing site to Novo Nordisk for USD200m
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine
Scancell reports promising SCOPE trial data for SCIB1 in advanced melanoma
Transgene teams up with ProBioGen for individualised cancer vaccines
Bio-Works Technologies AB secures LOI for vaccine manufacturing product
LakeShore Biopharma's Phase III YSJA Rabies Vaccine clinical trial receives Chinese NMPA approval